Objective: To assess the relationship between serum albumin level and clinical outcome in heart failure (HF) patients receiving cardiac resynchronization therapy (CRT). Methods: In this retrospective cohort study, 357 consecutive chronic heart failure patients receiving CRT between January 2010 and December 2015 were enrolled and divided into two groups based on pre-CRT serum albumin (albumin≥40 g/L, n=244; albumin<40 g/L, n=113). Clinical outcomes were defined as all-cause mortality (including heart transplantation) and rehospitalization due to worsening HF.Baseline characteristics were compared and all-cause mortality (including heart transplantation) and rehospitalization due to worsening heart failure (HF) were analyzed using Kaplan-Meier curves.Prognostic value of albumin level was evaluated in Cox proportional-hazards regression models. Results: Over a median follow-up time of 21 months, 45 patients (12.6%) died, 4 patients (1.1%) underwent heart transplantation and 100 patients (28.0%) were rehospitalized due to worsening HF. HF patients with pre-CRT albumin<40 g/L were related with worse NYHA function class, lower HDL-C level and ACEI/ARB use compared to HF patients with pre-CRT albumin≥40 g/L. Kaplan-Meier analyses evidenced lower survival rate in HF patients (log-rank test: P=0.000 4, χ(2)=12.60) and higher rehospitalization rate due to worsening HF (log-rank test: P=0.009, χ(2)=6.82) in HF patients with pre-CRT albumin<40 g/L.Multivariate Cox analyses indicated that serum pre-CRT albumin <40 g/L was an independent risk factor for all-cause mortality (HR=2.019, 95%CI 1.125-3.622, P=0.018) and HF rehospitalization (HR=1.517, 95%CI 1.014-2.270, P=0.043). Conclusion: Pre-CRT serum albumin level is associated with the severity of heart failure in CRT recipients.Patients with lower pre-CRT albumin level face increased risk of all-cause mortality and HF rehospitalization in chronic heart failure patients receiving cardiac resynchronization.
目的: 探讨血清白蛋白水平与接受心脏再同步化治疗(CRT)的心力衰竭(心衰)患者临床预后的关系。 方法: 本研究为回顾性研究。连续入选阜外医院2010年1月至2015年12月首次行CRT植入术的心衰患者357例,收集其临床资料,并进行随访。随访终点定义为全因死亡(包括心脏移植)和心衰再住院。根据患者CRT术前血清白蛋白水平将患者分为白蛋白≥ 40 g/L组(n=244)与白蛋白<40 g/L组(n=113),比较两组患者基线资料。对随访结果作生存分析和Cox回归分析以评价白蛋白水平对各终点事件的预测价值。 结果: 随访结束时共45例患者(12.6%)死亡,4例(1.1%)行心脏移植,100例(28.0%)出现心衰再住院。两组患者相比,白蛋白<40 g/L组患者纽约心脏协会(NYHA)心功能Ⅱ级较少,而NYHA心功能Ⅲ级患者较多。白蛋白≥40 g/L组患者血管紧张素转换酶抑制剂(ACEI)/血管紧张素Ⅱ受体拮抗剂(ARB)类药物使用率、血高密度脂蛋白胆固醇(HDL-C)水平较高。Kaplan-Meier生存分析结果显示白蛋白<40 g/L组患者在全因死亡(log-rank检验:P=0.000 4, χ(2)=12.60)和心衰再入院(log-rank检验:P=0.009, χ(2)= 6. 82)方面均劣于白蛋白≥ 40 g/L组。多因素Cox回归分析发现血清白蛋白<40 g/L是CRT患者全因死亡(HR=2.019, 95%CI 1.125~3.622, P=0.018)和心衰再住院(HR=1.517, 95%CI 1.014~2.270, P=0.043)的独立危险因素。 结论: 血清白蛋白水平与心衰CRT患者的严重程度相关,术前血清白蛋白水平较低的心衰CRT患者全因死亡及心衰再住院风险较大。.
Keywords: Cardiac resynchronization therapy; Heart failure; Risk factors; Serum albumin.